C-reactive protein and outcomes in acute coronary syndromes: A systematic review and meta-analysis

Arquivos Brasileiros de Cardiologia

Volumn 97, Issue 1, 2011, Pages

  Correia, Luís C L ^a   Esteves, Péricles J ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Acute coronary syndrome; C reactive protein; Meta analysis; Prognosis

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIAC PATIENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MEDLINE; META ANALYSIS (TOPIC); MULTIVARIATE ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK; STRATIFICATION; SYSTEMATIC REVIEW (TOPIC); META ANALYSIS; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; ODDS RATIO; PROGNOSIS; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 80052757007     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343 (16): 1139-47.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105 (9): 1135-43.
3. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002; 347 (1): 5-12.
4. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated highsensitivity C-reactive protein assay. Clin Chem. 1999; 45 (12): 2136-41.
5. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al; NACB WRITING GROUP. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation. 2007; 115 (13): e356-e375.
6. Nicolau JC, Timerman A, Piegas LS, Marin Neto JA, Rassi A Jr. Guidelines for unstable angina and non-ST-segment elevation myocardial infarction of the Brazilian Society of Cardiology (II Edition,2007). Arq Bras Cardiol.2007; 89 (4): e89-e131.
7. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DEJ, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non- ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007; 50 (7): e1-e157.
8. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007; 28 (13): 1598-660.
9. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006; 6: 31.
10. Bax L, Yu LM, Ikeda N, Moons KG. A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med Res Methodol. 2007; 7: 40.
11. Tanaka H, Tsurumi Y, Kasanuki H. Prognostic value of C-reactive protein and troponin T level in patients with unstable angina pectoris. J Cardiol. 2006; 47 (4): 173-9.
12. Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukahara K, Okuda J, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J. 2007; 71 (2): 186-90.
13. Baeza VR, Corbalan HR, Castro GP, Acevedo BM, Quiroga GT, Viviani GP. Coronary biomarkers and long-term clinical outcome in acute coronary syndrome without ST segment elevation. Rev Med Chil. 2005; 133 (11): 1285-93.
14. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331 (7): 417-24.
15. Oltrona L, Ardissino D, Merlini PA, Spinola A, Chiodo F, Pezzano A. C-reactive protein elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol. 1997; 80 (8): 1002-6.
16. Benamer H, Steg PG, Benessiano J, Vicaut E, Gaultier CJ, Boccara A, et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol. 1998; 82 (7): 845-50.
17. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998; 31 (7): 1460-5.
18. de Winter RJ, Bholasingh R, Lijmer JG, Koster RW, Gorgels JP, Schouten Y, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res. 1999; 42 (1): 240-5.
19. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. 2000; 35 (6): 1535-42.
20. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol. 2003; 41 (6): 916-24.
21. Oltrona L, Ottani F, Galvani M. Clinical significance of a single measurement of troponin-I and C-reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. Am Heart J. 2004; 148 (3): 405-15.
22. Bodi V, Sanchis J, Llacer A, Facila L, Nunez J, Bertomeu V, et al. Risk stratification in non-ST elevation acute coronary syndromes: predictive power of troponin I, C-reactive protein, fibrinogen and homocysteine. Int J Cardiol. 2005; 98 (2): 277-83.
23. Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, Verret B, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol. 2008; 51 (24): 2339-46.
24. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007; 53 (1): 1800-7.
25. Kuch B, von Scheidt W, Kling B, Heier M, Hoermann A, Meisinger C. Differential impact of admission C-reactive protein levels on 28-day mortality risk in patients with ST-elevation versus non-ST-elevation myocardial infarction (from the Monitoring Trends and Determinants on Cardiovascular Diseases [MONICA]/Cooperative Health Research in the Region of Augsburg [KORA] Augsburg Myocardial Infarction Registry). Am J Cardiol. 2008; 102 (9): 1125-30.
26. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, Katsaros K, et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol. 2005; 96 (4): 533-7.
27. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after Non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002; 105 (12): 1412-5.
28. Duarte ER, Pellanda LC, Portal VL. Inflammatory, lipid, and metabolic profile in acute ischemic syndrome: correlation with hospital and posthospital events. Arq Bras Cardiol. 2005; 84 (2): 122-9.
29. Manenti ER, Bodanese LC, Camey SA, Polanczyk CA. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin Cardiol. 2006; 29 (9): 405-10.
30. Correia LC, Lima JC, Rocha MS, D'Oliveira JA, Pericles EJ. Does highsensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes? Clin Chim Acta. 2007; 375 (1-2): 124-8.
31. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 1999;100 (19): 1958-63.
32. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999; 99 (7): 855-60.
33. O'Donoghue M, Morrow DA. The future of biomarkers in the management of patients with acute coronary syndromes. Curr Opin Cardiol. 2008; 23 (4): 309-14.
34. Wilson PW. Challenges to improve coronary heart disease risk assessment. JAMA. 2009; 302 (21): 2369-70.
35. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006; 145 (1): 35-42.
36. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355 (25): 2631-9.